The RETpositive/LUNGevity Award for RET-Positive Lung Cancer Research supports high-impact research that seeks to transform the future for people diagnosed with RET-positive lung cancer by changing RET-positive lung cancer into a chronic or curable condition.

At the start of the award term, an applicant must:

  • Hold a doctoral degree
  • Have a faculty appointment with a university-based academic institution or a research institution that is not formally associated with a university

An applicant may be at any level of research experience.

The research project(s) that will be funded is (are) expected to have a direct impact on the outcomes of patients with advanced RET-positive lung cancer, but innovative proposals that address other unmet needs in the RET-positive lung cancer space are also invited for submission. Projects are to include at least one aim that is translational and must be directly related to improvement of patient outcomes and/or lead to a clinical trial. Projects using multikinase inhibitors will not be favorably reviewed.

RETpositive/LUNGevity Awards may be for a maximum of $200,000

  • $100,000 per year for 2 years
  • Annual milestones must be met

Note: Only one RETpositive/LUNGevity Award will be granted per institution.

LUNGevity uses a two-step application process:

  1. A letter of intent (LOI), with a brief overview of the proposed project and biographical information
  2. A full application with an extended narrative about the project, as well as supporting information and documentation. (Because the number of awards is limited, only a subset of applicants are invited to submit a full application after the LOI review is completed.)

Reviewers are drawn from our Scientific Advisory Board and other lung cancer experts. Awardees have progress and financial reporting obligations during their award term.

A complete description, terms and conditions, and instructions are included in the 2022 RETpositive/LUNGevity Award for RET-positive Lung Cancer Research RFA.  All application materials must be submitted electronically via proposalCENTRAL.

2022 RETpositive/LUNGevity Award Timeline

LOIs due: by September 17, 2021, 11:59 pm EST
Full application invitations: No earlier than October 11, 2021
Full application due (by invitation only):      November 05, 2021, 11:59 pm EDT     
Award announcement: No earlier than January 2022
Anticipated year-one funding: No earlier than February 2022